Nu Tests US Market Entry as Capital Discipline Remains Under Scrutiny

What happened

Nu has launched initial US banking products, including high-yield deposits and no-fee rewards, marking a concrete step beyond its Latin American core. This follows earlier conditional OCC approval and extends its digital banking model into a new competitive landscape. The move comes at a time when Nu already faces rising credit costs and capital compression in Brazil, with CET1 falling to 11.3% and risk-adjusted NIM declining to 9.5% in Q1 2026. The DeepValue master report maintained a wait rating, citing the need for stabilization in Brazil's capital ratios, NPL trends, and margin recovery before adding exposure. The US entry adds another layer of execution and capital demand, testing whether the Latin American playbook can scale globally without straining core operations.

Implication

The US product launch expands Nu's addressable market but requires significant investment and management focus at a time when Brazil capital ratios are under pressure. Early US traction may be slow given intense competition and a different regulatory landscape, and the high-yield deposit strategy could compress margins if not matched by lending scale. The core investment case still hinges on Brazil CET1 stabilizing above 11.3% and risk-adjusted NIM recovering from 9.5%, which have not yet shown improvement. Investors should treat US expansion as an optionality that is now consuming real resources, not a near-term earnings driver. Until core credit metrics improve, the stock remains a wait; any deterioration in Brazil or Mexico plus US execution missteps could shift to a sell.

Thesis delta

The prior thesis held a wait stance due to capital intensity and credit uncertainty in Brazil and Mexico. The news of a concrete US product launch adds execution and capital allocation risk, but it does not alter the fundamental wait rating. US optionality is becoming operational, requiring monitoring for distraction and capital consumption, but the core conditions for a buy—Brazil CET1 stabilization, risk-adjusted NIM recovery, and no further NPL rise—remain unchanged.